Approved Research

Identification and validation of putative therapeutic targets in respiratory disease

Lay summary

Therapies aimed at drug targets with support from genetic evidence are more likely to be both safe and effective. We aim to generate detailed knowledge on lung diseases using a broad range of data in UK Biobank and to perform genetic analyses of those diseases to support identification of the next generation of drug targets. This is an ongoing partnership between academic scientists at the Universities of Leicester and Nottingham and GlaxoSmithKline, where we aim to apply cutting edge scientific approaches, publish our findings for the benefit of the wider community and translate our findings towards new therapies to benefit patients.